APP and Alzheimer disease: In addition, in an APP mice model of AD, chronic VU0486846 administration resulted in reduced levels of Aβ, rescue of cognitive deficits, and a shift in APP processing from amyloidogenic to non-amyloidogenic cleavage [134].